PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action
Event:
ESC Congress 2021 - The Digital Experience
Topic:
Lipid-Lowering Agents
Session:
Congress committee e-posters choice in pharmacology and pharmacotherapy
